Nucleoside LINE-1 Inhibitors for Cancer and Neurodegenerative Diseases
Summary
The European Patent Office published patent application EP4499106A2 for nucleoside LINE-1 inhibitors filed by Transposon Therapeutics, Inc. The patent covers novel therapeutic compounds targeting LINE-1 retrotransposons with applications in cancer treatment and neurodegenerative diseases. Publication includes international classifications spanning organic chemistry (C07D), nucleosides (C07H), and pharmaceutical preparations (A61K).
What changed
The EPO published patent application EP4499106A2 filed by Transposon Therapeutics, Inc. covering nucleoside compounds that inhibit LINE-1 (Long Interspersed Nuclear Element-1) retrotransposons. The application includes 8 inventors and lists therapeutic indications in cancer (A61P35/00), neurodegenerative diseases (A61P25/28), and immune disorders (A61P37/00). Designated states cover all EPO member states including DE, FR, GB, IT, NL, ES, PL, and 24 others.
This is a routine patent publication notice with no compliance obligations. Pharmaceutical companies developing retrotransposon-targeting therapies should review the patent claims to assess potential freedom-to-operate implications. Drug manufacturers in the oncology and neuroscience space may need to evaluate whether their research programs intersect with the disclosed nucleoside inhibitor structures.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NUCLEOSIDE LINE-1 INHIBITORS
Publication EP4499106A2 Kind: A2 Mar 25, 2026
Applicants
Transposon Therapeutics, Inc.
Inventors
WEBER, Eckard, CORDINGLEY, Michael, G., BURNIE, Andrew, James, BROWN, William, DARAPANENI, Chandra Mohan, PALADINO, Marco, DOSHI, Malay, PATEL, Jigneshkumar Jashbhai
IPC Classifications
C07D 405/04 20060101AFI20260213BHEP C07D 409/04 20060101ALI20260213BHEP C07D 473/00 20060101ALI20260213BHEP C07D 487/04 20060101ALI20260213BHEP C07H 19/056 20060101ALI20260213BHEP C07H 19/067 20060101ALI20260213BHEP C07H 19/073 20060101ALI20260213BHEP C07H 19/167 20060101ALI20260213BHEP C07H 19/173 20060101ALI20260213BHEP C07H 19/23 20060101ALI20260213BHEP A61K 31/522 20060101ALI20260213BHEP A61K 31/519 20060101ALI20260213BHEP C07F 9/6561 20060101ALI20260213BHEP A61K 31/513 20060101ALI20260213BHEP A61P 25/28 20060101ALI20260213BHEP A61P 35/00 20060101ALI20260213BHEP A61P 37/00 20060101ALI20260213BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.